Taking a continuous 168-day course of oral contraceptives (OCs) can reduce symptoms of premenstrual syndrome, or PMS, compared to the 21/7-day regimen, according to the results of a study published in the November issue of the American Journal of Obstetrics and Gynecology.
Taking a continuous 168-day course of oral contraceptives (OCs) can reduce symptoms of premenstrual syndrome, or PMS, compared to the 21/7-day regimen, according to the results of a study published in the November issue of the American Journal of Obstetrics and Gynecology.
Andrea L. Coffee, PharmD, of Scott & White Memorial Hospital in Temple, Tex., and colleagues conducted a study of 111 women who had switched from a 21/7-day regimen of an OC containing 3 mg of drosperinone and 30 μg of ethinylestradiol to a continuous 168-day regimen.
A subgroup of 55 women (54%) with the greatest cyclical variation in physical symptoms and mood swings was identified and taken to resemble patients with premenstrual syndrome. Those women who experienced the most severe cyclic variability when taking the OCs on a 21/7-day basis benefited the most from a 168-day regimen, with the biggest improvement noted during the 6th month.
Coffee AL, Kuehl TJ, Willis S, et al. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol. 2006;195:1311-1319.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More